Next-gen antibody experts at AnaptysBio file $86M IPO
John Carroll
Up to now, San Diego-based AnaptysBio has raised close to $ 49 million in cash directly from collaborators looking to the antibody shop to use their technology to create ...
Tesaro gets a green light for rolapitant, triggering Merck showdown
John Carroll
The FDA has given Tesaro a green light to start marketing rolapitant to help prevent some of the common side effects of chemotherapy. And now Tesaro will wage a David-vs.-Goliath ...
Report: Real-world Blincyto spending likely to fall far short of Amgen’s $178K list price
Tracy Staton
When Amgen rolled out its Blincyto treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering price–$ 178,000 ...
AbbVie hands United a record $350M payoff for a speedy FDA review voucher
John Carroll
The cost of a priority review voucher for the FDA keeps going up. AbbVie is forking over a record $ 350 million to acquire a voucher from United Therapeutics, giving them ...
Gene therapy stalwart ReGenX plots a $100M IPO to strike out on its own
Damian Garde
After years of outlicensing its gene therapy technology, ReGenX Bio is pressing forward with treatments of its own, filing to raise $ 100 million in an IPO to fund ...
NICE plots takeover of England’s Cancer Drugs Fund
Emily Wasserman
England's Cancer Drugs Fund has been dealing with budget overruns and backlash from drugmakers and patients unhappy with the fund's decision to ax certain meds ...
Probing lawmakers grill Valeant on price hikes
Carly Helfand
A pair of lawmakers is taking a look into recent drug price increases–and as part of the investigation, it wants some information from Valeant.
FiercePharma News
Express Scripts: Pricey PCSK9 drugs poised to ‘wreak havoc’
Carly Helfand
Last week, Sanofi revealed a $ 14,600 sticker for new PCSK9 med Praluent that far exceeded the price tag analysts expected. And unsurprisingly, leading ...
UnitedHealth uses newfound scale to negotiate pay-for-performance deals
Carly Helfand
Newly bulked-up UnitedHealth now boasts the U.S.' third largest pharmacy benefits business–and it's using its scale to push for refunds when meds don't ...
You want a formal offer, Mylan? Teva could have one this week
Carly Helfand
Last month, Mylan Chairman Robert Coury challenged suitor Teva to either put up a formal bid or step aside and let his company proceed with its plan to pursue its own ...
Scientists dig up new evidence linking GSK’s Pandemrix with narcolepsy
Tracy Staton
A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike ...